Literature DB >> 14634620

Survivin, versatile modulation of cell division and apoptosis in cancer.

Dario C Altieri1.   

Abstract

Survivin is a member of the inhibitor of apoptosis (IAP) gene family that has attracted attention from several viewpoints of basic and translational research. Its cell cycle-regulated expression at mitosis and association with the mitotic apparatus have been of interest to cell biologists studying faithful segregation of sister chromatids and timely separation of daughter cells. Investigators interested in mechanisms of apoptosis have found survivin an evolving challenge: while survivin inhibits apoptosis in vitro and in vivo, this pathway may be more selective as compared to cytoprotection mediated by other IAPs. Finally, basic and translational researchers in cancer biology have converged on survivin as a pivotal cancer gene, not simply for its sharp expression in tumors and not in normal tissues, but also for the potential exploitation of this pathway in cancer diagnosis and therapy. The objective of the present contribution is to line up current evidence and emerging concepts on the multifaceted functions of survivin in cell death and cell division, and how this pathway is being pursued for novel cancer therapeutic strategies.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14634620     DOI: 10.1038/sj.onc.1207113

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  265 in total

1.  Immunoexpression of Survivin in non-neoplastic lymphoid tissues and malignant lymphomas using a new monoclonal antibody reactive on paraffin sections.

Authors:  José Vassallo; Talal Al Saati; Randy D Gascoyne; Kathyrn Welsh; John C Reed; Pierre Brousset; Georges Delsol
Journal:  J Hematop       Date:  2010-01-30       Impact factor: 0.196

2.  Inducible suppression of Fgfr2 and Survivin in ES cells using a combination of the RNA interference (RNAi) and the Cre-LoxP system.

Authors:  Xavier Coumoul; Wenmei Li; Rui-Hong Wang; Chuxia Deng
Journal:  Nucleic Acids Res       Date:  2004-06-15       Impact factor: 16.971

Review 3.  Biomolecular predictors of urothelial cancer behavior and treatment outcomes.

Authors:  Michael Rink; Eugene K Cha; David Green; Jens Hansen; Brian D Robinson; Yair Lotan; Arthur I Sagalowsky; Felix K Chun; Pierre I Karakiewicz; Margit Fisch; Douglas S Scherr; Shahrokh F Shariat
Journal:  Curr Urol Rep       Date:  2012-04       Impact factor: 3.092

4.  Biological effects of ray cartilage extract on human breast cancer cell line MCF-7 and its mechanism.

Authors:  De-Miao Zhu; Wan-Li Xue; Wei Tao; Jin-Cheng Li
Journal:  Int J Clin Exp Med       Date:  2015-05-15

Review 5.  Survivin as a novel target protein for reducing the proliferation of cancer cells.

Authors:  Dongyu Li; Chenghao Hu; Huibin Li
Journal:  Biomed Rep       Date:  2018-03-13

6.  Matrix metalloproteinase 2-sensitive multifunctional polymeric micelles for tumor-specific co-delivery of siRNA and hydrophobic drugs.

Authors:  Lin Zhu; Federico Perche; Tao Wang; Vladimir P Torchilin
Journal:  Biomaterials       Date:  2014-02-13       Impact factor: 12.479

7.  Selenium inhibition of survivin expression by preventing Sp1 binding to its promoter.

Authors:  Jae Yeon Chun; Yan Hu; Elaine Pinder; Jianguo Wu; Fengzhi Li; Allen C Gao
Journal:  Mol Cancer Ther       Date:  2007-09       Impact factor: 6.261

8.  Survivin expression in early hepatocellular carcinoma and post-treatment with anti-cancer drug under hypoxic culture condition.

Authors:  Satoshi Mamori; Tadashi Asakura; Kiyoshi Ohkawa; Hisao Tajiri
Journal:  World J Gastroenterol       Date:  2007-10-28       Impact factor: 5.742

9.  Absence of FHIT expression is associated with apoptosis inhibition in colorectal cancer.

Authors:  Jie Cao; Xiaoping Chen; Wanglin Li; Jie Xia; Hong Du; Weibiao Tang; Shanming Chen; Hui Wang; Xiwen Chen; Huanqing Xiao; Yuyuan Li
Journal:  Front Med China       Date:  2007-05-01

10.  Survivin rs9904341 (G>C) polymorphism contributes to cancer risk: an updated meta-analysis of 26 studies.

Authors:  Lei Xu; Xin Zhou; Lin Xu; Rong Yin
Journal:  Tumour Biol       Date:  2013-10-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.